Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients

Keyphrases

• Cancer Patients 100%
• Head-and-neck Cancer 100%
• Head-and-neck Squamous Cell Carcinoma (HNSCC) 100%
• P53 Status 100%
• Co-mutation 100%
• Immunosignature 100%
• Immune Checkpoint Inhibitors 50%
• Immune Gene Expression 50%
• Gene Signature 33%
• TP53 Gene 33%
• Tumor 16%
• TP53 mutation 16%
• Clinical Setting 16%
• Tumor Protein p53 (TP53) 16%
• Gene TP53 16%
• Signaling Pathway 16%
• Driver mutations 16%
• Patient Cohort 16%
• PD-L1 Inhibitor 16%
• In Vitro Experiment 16%
• Therapeutic Strategies 16%
• Gene Set 16%
• Therapeutic Benefits 16%
• Cell Composition 16%
• Signature Sets 16%
• HPV Negative 16%
• Validation Analysis 16%
• Immune Gene Signature 16%
• Co-driver 16%
• HNSCC Cell Lines 16%

Biochemistry, Genetics and Molecular Biology

• Immune Checkpoints 100%
• Gene Expression Profiling 66%
• Gene Expression 33%
• Gene Signature 33%
• PD-L1 33%